NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma (Nasdaq: NAMS) announced that its Compensation Committee has approved inducement share options for five non-executive new hires, covering 133,000 ordinary shares. The options were granted under the company's 2024 Inducement Plan and comply with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price of $18.38 per share, matching the closing market price on April 1, 2025. The vesting schedule spans four years, with 25% vesting after one year and the remaining balance vesting in 36 monthly installments, contingent on continued employment.
NewAmsterdam Pharma (Nasdaq: NAMS) ha annunciato che il suo Comitato per la Compensazione ha approvato opzioni di azioni di indennizzo per cinque nuove assunzioni non esecutive, coprendo 133.000 azioni ordinarie. Le opzioni sono state concesse nell'ambito del Piano di Indennizzo 2024 dell'azienda e sono conformi alla Regola di Quotazione Nasdaq 5635(c)(4).
Le opzioni azionarie hanno un prezzo di esercizio di $18.38 per azione, corrispondente al prezzo di chiusura di mercato del 1 aprile 2025. Il programma di maturazione si estende su quattro anni, con il 25% che matura dopo un anno e il saldo rimanente che matura in 36 rate mensili, a condizione di continuare a essere impiegati.
NewAmsterdam Pharma (Nasdaq: NAMS) anunció que su Comité de Compensación ha aprobado opciones de acciones de inducción para cinco nuevas contrataciones no ejecutivas, cubriendo 133,000 acciones ordinarias. Las opciones fueron otorgadas bajo el Plan de Inducción 2024 de la compañía y cumplen con la Regla de Cotización Nasdaq 5635(c)(4).
Las opciones de acciones tienen un precio de ejercicio de $18.38 por acción, coincidiendo con el precio de cierre del mercado del 1 de abril de 2025. El cronograma de adquisición se extiende por cuatro años, con un 25% que se adquiere después de un año y el saldo restante que se adquiere en 36 cuotas mensuales, condicionado a la continuidad del empleo.
NewAmsterdam Pharma (Nasdaq: NAMS)는 보상 위원회가 다섯 명의 비임원 신규 채용자에게 유도 주식 옵션을 승인했다고 발표했습니다. 이 옵션은 133,000주에 해당하며, 회사의 2024 유도 계획에 따라 부여되었으며, Nasdaq 상장 규칙 5635(c)(4)에 부합합니다.
주식 옵션의 행사가격은 $18.38로, 2025년 4월 1일의 마감 시장 가격과 일치합니다. 권리 행사 일정은 4년에 걸쳐 있으며, 1년 후에 25%가 부여되고 나머지 잔액은 계속 고용되는 조건으로 36개월에 걸쳐 매달 부여됩니다.
NewAmsterdam Pharma (Nasdaq: NAMS) a annoncé que son Comité de Rémunération a approuvé des options d'actions d'incitation pour cinq nouvelles recrues non exécutives, couvrant 133 000 actions ordinaires. Les options ont été accordées dans le cadre du Plan d'Incitation 2024 de l'entreprise et sont conformes à la Règle de Cotation Nasdaq 5635(c)(4).
Les options d'actions ont un prix d'exercice de $18.38 par action, correspondant au prix de clôture du marché du 1er avril 2025. Le calendrier d'acquisition s'étend sur quatre ans, avec 25 % d'acquisition après un an et le solde restant acquis en 36 versements mensuels, sous réserve de la continuité de l'emploi.
NewAmsterdam Pharma (Nasdaq: NAMS) gab bekannt, dass ihr Vergütungsausschuss Induktionsaktienoptionen für fünf neue nicht-executive Mitarbeiter genehmigt hat, die 133.000 Stammaktien abdecken. Die Optionen wurden im Rahmen des 2024 Induktionsplans des Unternehmens gewährt und entsprechen der Nasdaq-Listing-Regel 5635(c)(4).
Die Aktienoptionen haben einen Ausübungspreis von $18.38 pro Aktie, was dem Schlusskurs am 1. April 2025 entspricht. Der Vesting-Zeitplan erstreckt sich über vier Jahre, wobei 25% nach einem Jahr und der verbleibende Betrag in 36 monatlichen Raten fällig wird, vorausgesetzt, die Beschäftigung bleibt bestehen.
- Successful recruitment of five new non-executive employees strengthening the company's workforce
- Potential dilution of existing shareholders through 133,000 new share options
NAARDEN, the Netherlands and MIAMI, April 04, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam’s Board of Directors approved the grant of inducement share options covering an aggregate of 133,000 of NewAmsterdam’s ordinary shares to five non-executive new hires. The share options were granted as an inducement material to the employees’ acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price per share equal to
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com
FAQ
How many shares are covered by NAMS's latest inducement options grant?
What is the exercise price for NAMS's April 2025 inducement share options?
What is the vesting schedule for NewAmsterdam Pharma's 2024 Inducement Plan options?
Under which regulatory rule were NAMS's inducement options granted?
